Rhumbline Advisers Akebia Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $105 Billion
  • Q2 2024

A detailed history of Rhumbline Advisers transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 247,060 shares of AKBA stock, worth $494,120. This represents 0.0% of its overall portfolio holdings.

Number of Shares
247,060
Previous 4,926 4915.43%
Holding current value
$494,120
Previous $9,000 2700.0%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024
BUY
$0.86 - $1.63 $208,235 - $394,678
242,134 Added 4915.43%
247,060 $252,000
Q2 2023

Aug 08, 2023
BUY
$0.51 - $1.43 $2,512 - $7,044
4,926 New
4,926 $4,000
Q2 2022

Aug 11, 2022
SELL
$0.32 - $0.67 $65,619 - $137,391
-205,062 Closed
0 $0
Q1 2022

May 12, 2022
SELL
$0.72 - $2.93 $4,358 - $17,735
-6,053 Reduced 2.87%
205,062 $147,000
Q4 2021

Feb 10, 2022
BUY
$2.26 - $3.34 $1,819 - $2,688
805 Added 0.38%
211,115 $477,000
Q3 2021

Nov 12, 2021
BUY
$2.35 - $3.88 $17,274 - $28,521
7,351 Added 3.62%
210,310 $606,000
Q2 2021

Aug 05, 2021
BUY
$2.83 - $4.2 $81,271 - $120,615
28,718 Added 16.48%
202,959 $769,000
Q1 2021

May 06, 2021
SELL
$2.92 - $5.06 $43,332 - $75,090
-14,840 Reduced 7.85%
174,241 $590,000
Q4 2020

Feb 10, 2021
BUY
$2.22 - $3.78 $29,004 - $49,385
13,065 Added 7.42%
189,081 $529,000
Q3 2020

Nov 12, 2020
SELL
$2.39 - $13.08 $79,307 - $434,033
-33,183 Reduced 15.86%
176,016 $442,000
Q2 2020

Aug 13, 2020
SELL
$6.67 - $13.58 $36,631 - $74,581
-5,492 Reduced 2.56%
209,199 $2.84 Million
Q1 2020

May 06, 2020
BUY
$4.1 - $10.24 $126,234 - $315,279
30,789 Added 16.74%
214,691 $1.63 Million
Q4 2019

Feb 05, 2020
BUY
$3.16 - $6.73 $20,995 - $44,714
6,644 Added 3.75%
183,902 $1.16 Million
Q3 2019

Oct 23, 2019
BUY
$3.55 - $5.4 $57,009 - $86,718
16,059 Added 9.96%
177,258 $695,000
Q2 2019

Aug 14, 2019
BUY
$4.1 - $8.05 $200,485 - $393,636
48,899 Added 43.54%
161,199 $780,000
Q1 2019

May 01, 2019
SELL
$5.41 - $8.73 $49,214 - $79,416
-9,097 Reduced 7.49%
112,300 $920,000
Q4 2018

Jan 31, 2019
BUY
$5.39 - $9.15 $410,518 - $696,891
76,163 Added 168.38%
121,397 $671,000
Q3 2018

Nov 07, 2018
SELL
$7.44 - $10.65 $17,952 - $25,698
-2,413 Reduced 5.06%
45,234 $399,000
Q2 2018

Aug 06, 2018
BUY
$9.15 - $11.34 $60,435 - $74,900
6,605 Added 16.09%
47,647 $476,000
Q1 2018

May 02, 2018
BUY
$9.53 - $15.68 $2,573 - $4,233
270 Added 0.66%
41,042 $391,000
Q4 2017

Feb 09, 2018
SELL
$14.24 - $19.59 $56,860 - $78,222
-3,993 Reduced 8.92%
40,772 $606,000
Q3 2017

Nov 06, 2017
BUY
$13.06 - $19.67 $584,630 - $880,527
44,765
44,765 $881,000

Others Institutions Holding AKBA

# of Institutions
110
Shares Held
55M
Call Options Held
554K
Put Options Held
246K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $368M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email